ADAM9, ADAM metallopeptidase domain 9, 8754

N. diseases: 109; N. variants: 6
Disease: Tumor Progression ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.050 AlteredExpression phenotype BEFREE The transmembrane protease ADAM9 is frequently upregulated in human cancers, and it promotes tumour progression in mice. 29142101 2018
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.050 Biomarker phenotype BEFREE This review summarizes the present knowledge on ADAM9 in solid cancers, and the different mechanisms which it employ to drive tumor progression. 29550974 2018
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.050 AlteredExpression phenotype BEFREE A human proteinase array assay was conducted to elucidate the potential effects of galangin, and the obtained results demonstrated that treatment of galangin inhibited ADAM9 protein expression and mRNA expression, that are known to contribute to cancer progression. 29115634 2018
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.050 Biomarker phenotype BEFREE ADAM9 (A Disintegrin And Metalloprotease 9) is a membrane-anchored metalloproteinase that has been implicated in pathological retinal neovascularization and in tumor progression. 28264989 2017
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.050 AlteredExpression phenotype BEFREE ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression. 18582378 2008